{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:46:57Z","timestamp":1786546017353,"version":"build-2736575974"},"reference-count":110,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1038\/ajg.2014.243","type":"journal-article","created":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T07:58:00Z","timestamp":1409644680000},"page":"1576-1584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Hepatitis C in African Americans"],"prefix":"10.14309","volume":"109","author":[{"given":"Sammy","family":"Saab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Francois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210210","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus in the United States, 1999 through 2002.","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"R2-13-20210210","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1478-3231.2011.02494.x","article-title":"Hepatitis C virus infection in USA: an estimate of true prevalence.","volume":"31","author":"Chak","year":"2011","journal-title":"Liver Int"},{"key":"R4-13-20210210","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/apt.12625","article-title":"The impact of hepatitis C burden: an evidence based approach.","volume":"39","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R5-13-20210210","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.510300319","article-title":"Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group.","volume":"30","author":"Reddy","year":"1999","journal-title":"Hepatology"},{"key":"R6-13-20210210","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/cid\/cir306","article-title":"All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population.","volume":"53","author":"El-Kamary","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R7-13-20210210","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/gut.2006.113217","article-title":"Study Group. Ramsay S, Thomson BJ et al. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study.","volume":"56","author":"Neal","year":"2007","journal-title":"Gut"},{"key":"R9-13-20210210","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.clinthera.2011.07.008","article-title":"Economic burden associated with patients diagnosed with hepatitis C.","volume":"33","author":"McCombs","year":"2011","journal-title":"Clin Ther"},{"key":"R10-13-20210210","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.","volume":"160","author":"Denniston","year":"2014","journal-title":"Ann Intern Med"},{"key":"R11-13-20210210","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update.","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R12-13-20210210","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199903113401001","article-title":"Rising incidence of hepatocellular carcinoma in the United States.","volume":"340","author":"El-Serag","year":"1999","journal-title":"N Engl J Med"},{"key":"R13-13-20210210","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/cid\/cit642","article-title":"Causes of death and characteristics of decedents with viral hepatitis, United States, 2010.","volume":"58","author":"Ly","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R14-13-20210210","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.cgh.2011.05.028","article-title":"Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C.","volume":"9","author":"Ng","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R15-13-20210210","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"key":"R16-13-20210210","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hep.23000","article-title":"Effect of hepatitis C virus and its treatment on survival.","volume":"50","author":"Butt","year":"2009","journal-title":"Hepatology"},{"key":"R17-13-20210210","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.","volume":"9","author":"Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R18-13-20210210","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28 B predicts hepatitis C treatment-induced viral clearance.","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"R19-13-20210210","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2036.2012.05145.x","article-title":"Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients.","volume":"36","author":"Rangnekar","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-13-20210210","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","article-title":"Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.","volume":"131","author":"Conjeevaram","year":"2006","journal-title":"Gastroenterology"},{"key":"R21-13-20210210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2008.05.020","article-title":"Virahep-C Study Group. Prospective analysis of effector and regulatory CD4 T cells in chronic HCV patients undergoing combination antiviral therapy.","volume":"49","author":"Burton","year":"2008","journal-title":"J Hepatol"},{"key":"R22-13-20210210","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.21714","article-title":"Virahep-C Study Group. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy.","volume":"46","author":"Rosen","year":"2007","journal-title":"Hepatology"},{"key":"R23-13-20210210","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/hep.24556","article-title":"Virahep-C Study Group. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C.","volume":"54","author":"Golden-Mason","year":"2011","journal-title":"Hepatology"},{"key":"R24-13-20210210","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/gene.2009.26","article-title":"Virahep-C Study. Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection.","volume":"10","author":"Yee","year":"2009","journal-title":"Genes Immun"},{"key":"R25-13-20210210","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","article-title":"Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanics whites.","volume":"350","author":"Muir","year":"2004","journal-title":"N Engl J Med"},{"key":"R26-13-20210210","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States,1988 through 1994.","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"R27-13-20210210","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1053\/gast.2000.19582","article-title":"Hepatitis C in African Americans: summary of a workshop.","volume":"119","author":"Howell","year":"2000","journal-title":"Gastroenterology"},{"key":"R28-13-20210210","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1478-3231.2006.01438.x","article-title":"Treating Hepatitis C in African Americans.","volume":"27","author":"Jeffers","year":"2007","journal-title":"Liver International"},{"key":"R29-13-20210210","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/jmv.23399","article-title":"Distribution of hepatitis C virus genotypes in a diverse US integrated health care population.","volume":"84","author":"Manos","year":"2012","journal-title":"J Med Virol"},{"key":"R30-13-20210210","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"R31-13-20210210","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2012.05.011","article-title":"Factors that predict response of patients with hepatitis C virus infection to boceprevir.","volume":"143","author":"Poordad","year":"2012","journal-title":"Gastroenterology"},{"key":"R32-13-20210210","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.25842","article-title":"Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.","volume":"56","author":"Gordon","year":"2012","journal-title":"Hepatology"},{"key":"R34-13-20210210","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3748\/wjg.v13.i7.1074","article-title":"Hepatitis C risk assessment, testing and referral for treatment in urban primary care: role of race ethnicity.","volume":"13","author":"Trooskin","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R35-13-20210210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2105\/AJPH.2012.300858","article-title":"Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010.","volume":"103","author":"Tohme","year":"2013","journal-title":"Am J Public Health"},{"key":"R36-13-20210210","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10620-010-1455-3","article-title":"Formal patient education improves patient knowledge of hepatitis C in vulnerable populations.","volume":"56","author":"Surjadi","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R37-13-20210210","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1007\/s10620-006-9579-1","article-title":"Reasons why patients infected with chronic hepatitis Cirus choose to defer treatment: do they alter their decision with time?","volume":"52","author":"Khokhar","year":"2007","journal-title":"Dig Dis Sci"},{"key":"R38-13-20210210","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s10620-009-0806-4","article-title":"African Americans may differ in their reasons for declining hepatitis C therapy compared to non-African-Americans.","volume":"54","author":"Borum","year":"2009","journal-title":"Dig Dis Sci"},{"key":"R39-13-20210210","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/gut.2006.099150","article-title":"Rate and predictors of treatment prescription for hepatitis C.","volume":"56","author":"Butt","year":"2007","journal-title":"Gut"},{"key":"R40-13-20210210","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hep.24358","article-title":"Racial differences in hepatitis C treatment eligibility.","volume":"54","author":"Melia","year":"2011","journal-title":"Hepatology"},{"key":"R41-13-20210210","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/lt.500040606","article-title":"Race: a critical factor in organ donation, patient referral and selection and orthotopic liver transplantation.","volume":"4","author":"Eckhoff","year":"1998","journal-title":"Liver Tranplant Surg"},{"key":"R42-13-20210210","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.22223","article-title":"Racial disparity in liver disease: biological, cultural, or socioeconomic factors.","volume":"47","author":"Nguyen","year":"2008","journal-title":"Hepatology"},{"key":"R43-13-20210210","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJM199606273342602","article-title":"Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection.","volume":"334","author":"Conry-Cantilena","year":"1996","journal-title":"N Engl J Med"},{"key":"R44-13-20210210","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","article-title":"The natural history of hepatitis c virus infection: host, viral, and environmental factors.","volume":"284","author":"Thomas","year":"2000","journal-title":"JAMA"},{"key":"R45-13-20210210","first-page":"52","article-title":"The natural history of hepatitis C: clinical experiences.","volume":"24","author":"McHutchison","year":"1996","journal-title":"J Hepatol"},{"key":"R46-13-20210210","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","article-title":"Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.","volume":"340","author":"Kenny-Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"R47-13-20210210","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1097\/MCG.0b013e318238352b","article-title":"African americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data.","volume":"46","author":"Mir","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"R48-13-20210210","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"R49-13-20210210","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1111\/j.1572-0241.2001.04050.x","article-title":"Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County.","volume":"96","author":"Bonacini","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R50-13-20210210","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1542-3565(04)00162-4","article-title":"Racial differences in liver inflammation and fibrosis related to chronic hepatitis C.","volume":"2","author":"Crosse","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R51-13-20210210","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/hep.21335","article-title":"Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection.","volume":"44","author":"Fontana","year":"2006","journal-title":"Hepatology"},{"key":"R52-13-20210210","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10620-011-1908-3","article-title":"Histological versus clinical cirrhosis in chronic hepatitis C: does raceethnicity really matter?","volume":"57","author":"Kohla","year":"2012","journal-title":"Dig Dis Sci"},{"key":"R53-13-20210210","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cgh.2009.08.009","article-title":"Ethnicity and body mass index are associated with hepatitis C presentation and progression.","volume":"8","author":"Kallwitz","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R54-13-20210210","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1572-0241.2002.05555.x","article-title":"Hepatitis C infection in African Americans: its natural history and histological progression.","volume":"97","author":"Wiley","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R55-13-20210210","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1542-3565(04)00164-8","article-title":"A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans.","volume":"2","author":"Sterling","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R56-13-20210210","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/0003-4819-158-9-201305070-00604","article-title":"HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study.","volume":"158","author":"Kirk","year":"2013","journal-title":"Ann Intern Med"},{"key":"R57-13-20210210","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.cgh.2008.08.006","article-title":"Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C.","volume":"6","author":"Terrault","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R58-13-20210210","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2893.2011.01565.x","article-title":"End-stage renal disease and African American race are independent predictors of mild liver fibrosis in patients with chronic hepatitis C infection.","volume":"19","author":"Aslinia","year":"2012","journal-title":"J Viral Hepatitis"},{"key":"R59-13-20210210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0030-1247133","article-title":"Current strategy for staging and treatment: the BCLC update and future prospects.","volume":"30","author":"Forner","year":"2010","journal-title":"Semin Liver Dis"},{"key":"R60-13-20210210","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1002\/cncr.26063","article-title":"Persistent disparities in liver transplantation for patients with hepatocellular carcinoma in the United States, 1998 through 2007.","volume":"117","author":"Robbins","year":"2011","journal-title":"Cancer"},{"key":"R61-13-20210210","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/cncr.24936","article-title":"Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma.","volume":"116","author":"Yu","year":"2010","journal-title":"Cancer"},{"key":"R62-13-20210210","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1572-0241.2007.01634.x","article-title":"Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002.","volume":"103","author":"Siegel","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R63-13-20210210","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10620-007-9872-7","article-title":"Ethnic differences in hepatocellular carcinoma: implications for liver transplantation.","volume":"53","author":"Kemmer","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R64-13-20210210","first-page":"1934","article-title":"Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival.","volume":"98","author":"Sloane","year":"2006","journal-title":"J Natl Med Assoc"},{"key":"R65-13-20210210","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.surg.2012.07.008","article-title":"Racial disparity and their impact on hepatocellular cancer outcomes in inner-city New Orleans.","volume":"152","author":"Jan","year":"2012","journal-title":"Surgery"},{"key":"R66-13-20210210","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1572-0241.2005.41829.x","article-title":"Colorectal cancer in African Americans.","volume":"100","author":"Agrawal","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R67-13-20210210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1300\/J077v19n03_06","article-title":"Barriers to colorectal cancer screening among ethnically diverse high- and average risk individuals.","volume":"19","author":"Bastani","year":"2001","journal-title":"J Psychosoc Oncol"},{"key":"R68-13-20210210","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-139-10-200311180-00009","article-title":"The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.","volume":"139","author":"El-Serag","year":"2003","journal-title":"Ann Intern Med"},{"key":"R69-13-20210210","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"R70-13-20210210","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1542-3565(04)00353-2","article-title":"Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis.","volume":"2","author":"Nguyen","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R71-13-20210210","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.amjmed.2008.03.005","article-title":"Racial and ethnic variations in hepatocellular carcinoma incidence within the United States.","volume":"121","author":"Wong","year":"2008","journal-title":"Am J Med"},{"key":"R72-13-20210210","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cgh.2005.12.022","article-title":"Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000.","volume":"4","author":"Yu","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R73-13-20210210","first-page":"1934","article-title":"Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival.","volume":"98","author":"Sloane","year":"2006","journal-title":"J Natl Med Assoc"},{"key":"R74-13-20210210","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10620-007-9872-7","article-title":"Ethnic differences in hepatocellular carcinoma: implications for liver transplantation.","volume":"53","author":"Kemmer","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R75-13-20210210","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/ajg.2014.11","article-title":"3 et al. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States.","volume":"109","author":"Altekruse","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R76-13-20210210","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2008.02.028","article-title":"Indications for liver transplantation.","volume":"134","author":"OLeary","year":"2008","journal-title":"Gastroenterology"},{"key":"R77-13-20210210","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/01.sla.0000164077.77912.98","article-title":"Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience.","volume":"241","author":"Busuttil","year":"2005","journal-title":"Ann Surg"},{"key":"R78-13-20210210","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/lt.22461","article-title":"Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C.","volume":"18","author":"Saxena","year":"2012","journal-title":"Liver Transplant"},{"key":"R79-13-20210210","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/TP.0b013e318253f7fa","article-title":"Racial differences in fibrosis progression after HCV-related liver transplantation.","volume":"94","author":"Layden","year":"2012","journal-title":"Transplantation"},{"key":"R80-13-20210210","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/hep.26478","article-title":"Donor risk index for African American liver transplant recipients with hepatitis C virus.","volume":"58","author":"Shores","year":"2013","journal-title":"Hepatology"},{"key":"R81-13-20210210","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jamcollsurg.2007.12.019","article-title":"Does race influence outcomes after primary liver transplantation? A 23-year experience with 2,700 patients.","volume":"206","author":"Hong","year":"2008","journal-title":"J Am Coll Surg"},{"key":"R82-13-20210210","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1053\/j.gastro.2010.02.008","article-title":"Donor race does not predict graft failure after liver transplantation.","volume":"138","author":"Asrani","year":"2010","journal-title":"Gastroenterology"},{"key":"R83-13-20210210","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1001\/jama.2008.720","article-title":"Disparities in liver transplantation before and after introduction of the MELD score.","volume":"300","author":"Moylan","year":"2008","journal-title":"JAMA"},{"key":"R84-13-20210210","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection.","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"R85-13-20210210","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated Chronic hepatitis C virus infection.","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl Med"},{"key":"R86-13-20210210","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection.","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"R87-13-20210210","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1572-0241.2007.01092.x","article-title":"Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3.","volume":"102","author":"Shiffman","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R88-13-20210210","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2893.2005.00682.x","article-title":"Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 23, and this is not explained by more frequent dose reductions of interferon and ribavirin.","volume":"1","author":"Brau","year":"2006","journal-title":"J Viral Hepatitis"},{"key":"R89-13-20210210","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.11213","article-title":"Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study.","volume":"97","author":"Advani","year":"2003","journal-title":"Cancer"},{"key":"R90-13-20210210","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/ajg.2012.306","article-title":"Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.","volume":"107","author":"Jin","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R91-13-20210210","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2008.02.035","article-title":"Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection.","volume":"6","author":"Howell","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R92-13-20210210","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/hep.23489","article-title":"Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.","volume":"51","author":"Petta","year":"2010","journal-title":"Hepatology"},{"key":"R93-13-20210210","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28 B is associated with chronic hepatitis c and treatment failure: a genome-wide association study.","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"R94-13-20210210","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10552-008-9115-z","article-title":"Vitamin D insufficiency among African-Americans in the southeastern United States: implications for cancer disparities (United States).","volume":"19","author":"Egan","year":"2008","journal-title":"Cancer Causes Control"},{"key":"R95-13-20210210","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1468-1293.2007.00476.x","article-title":"The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis.","volume":"8","author":"Kim","year":"2007","journal-title":"HIV Med"},{"key":"R96-13-20210210","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1310\/hct1303-142","article-title":"Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.","volume":"13","author":"Rodriguez-Torres","year":"2012","journal-title":"HIV Clin Trials"},{"key":"R97-13-20210210","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/hep.20212","article-title":"Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.","volume":"39","author":"Jeffers","year":"2004","journal-title":"Hepatology"},{"key":"R98-13-20210210","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/infdis\/jit444","article-title":"Variants in HAVCR1 gene region contribute to hepatitis C Persistence in African Americans.","volume":"209","author":"Wojcik","year":"2014","journal-title":"J Infect Dis"},{"key":"R99-13-20210210","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.","volume":"464","author":"Fellay","year":"2010","journal-title":"Nature"},{"key":"R100-13-20210210","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.","volume":"31","author":"De Franceschi","year":"2000","journal-title":"Hepatology"},{"key":"R101-13-20210210","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/hep.27022","article-title":"ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.","volume":"59","author":"Holmes","year":"2014","journal-title":"Hepatology"},{"key":"R102-13-20210210","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study.","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatology"},{"key":"R103-13-20210210","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"R104-13-20210210","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"R105-13-20210210","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"R106-13-20210210","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2893.2005.00697.x","article-title":"Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response.","volume":"13","author":"Howell","year":"2006","journal-title":"J Viral Hepatitis"},{"key":"R107-13-20210210","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R108-13-20210210","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R109-13-20210210","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450r-ombitasvir and dasabuvir with ribavirin.","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"R110-13-20210210","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"R111-13-20210210","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450r-ombitasvir and dasabuvir with ribavirin.","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"R112-13-20210210","doi-asserted-by":"crossref","first-page":"S524","DOI":"10.1016\/S0168-8278(14)61461-6","article-title":"All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: Phase 3 HALLMARK-DUAL Study Results.","volume":"60","author":"Manns","year":"2014","journal-title":"J Hepatol"},{"key":"R114-13-20210210","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2014243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2014243","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2014243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201410000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:50:17Z","timestamp":1786542617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201410000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":110,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2014.243","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}